SGMT
HEALTHCARESagimet Biosciences Inc - Class A
Live · NASDAQ · May 9, Close
What's Moving SGMT Today?
No stock-specific AI insight has been generated for SGMT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.38
Fundamentals
Trading
SGMT News
20 articles- Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?Yahoo Finance·May 5, 2026
- Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?Yahoo Finance·May 5, 2026
- Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M RaiseMarketbeat·May 1, 2026
- Why Sagimet Biosciences Stock Is Soaring TodayMotley Fool·Apr 27, 2026
- Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion PlansAdvfn·Apr 27, 2026
- Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common StockYahoo Finance·Apr 27, 2026
- Sagimet Biosciences Provides Strategic and Corporate UpdatesYahoo Finance·Apr 27, 2026
- Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswire Inc.·Apr 20, 2026
- Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 6, 2026
- Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 ResultsYahoo Finance·Mar 25, 2026
- Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Mar 11, 2026
- Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf.Marketbeat·Mar 1, 2026
- Sagimet Biosciences Announces Participation in Three Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- Sagimet Biosciences Showcases FASN Strategy, MASH Phase II Timeline and Acne Data at Guggenheim ConferenceMarketbeat·Feb 15, 2026
- Sagimet Biosciences Announces Participation in Two Upcoming Investor ConferencesYahoo Finance·Feb 5, 2026
- A Look At Sagimet Biosciences (SGMT) Valuation After Denifanstat’s Phase 3 Acne Trial SuccessYahoo Finance·Feb 5, 2026
- Adobe downgraded, Palantir upgraded: Wall Street's top analyst callsYahoo Finance·Feb 3, 2026
- Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe AcneYahoo Finance·Feb 2, 2026
- Biotech Veteran and Virologist Joins CancerVax as Senior Scientific AdvisorYahoo Finance·Jan 27, 2026
- Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 ConferenceYahoo Finance·Jan 8, 2026
All 20 articles loaded
Price Data
52-Week Range
$8.38
Fundamentals
Trading
About Sagimet Biosciences Inc - Class A
Sagimet Biosciences Inc. (SGMT) is an innovative biotechnology company focused on developing transformative therapies for metabolic diseases, primarily targeting non-alcoholic steatohepatitis (NASH). The firm is progressing its lead therapeutic candidate through various clinical trial phases, utilizing unique mechanisms designed to enhance patient outcomes significantly. With a highly experienced leadership team and a robust intellectual property portfolio, Sagimet is strategically positioned to capitalize on the increasing market demand for effective metabolic disease treatments, making it an attractive investment opportunity for institutional investors seeking exposure in the dynamic biotech sector.